These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27185866)

  • 1. Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Ceccato F; Barbot M; Albiger N; Zilio M; De Toni P; Luisetto G; Zaninotto M; Greggio NA; Boscaro M; Scaroni C; Camozzi V
    Eur J Endocrinol; 2016 Aug; 175(2):101-6. PubMed ID: 27185866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy.
    Koetz KR; Ventz M; Diederich S; Quinkler M
    J Clin Endocrinol Metab; 2012 Jan; 97(1):85-92. PubMed ID: 21994966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone Mass in Young Patients with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.
    Espinosa Reyes TM; Leyva González G; Domínguez Alonso E; Falhammar H
    Horm Res Paediatr; 2021; 94(1-2):1-8. PubMed ID: 34044395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia.
    Falhammar H; Filipsson Nyström H; Wedell A; Brismar K; Thorén M
    Eur J Endocrinol; 2013 Mar; 168(3):331-41. PubMed ID: 23211577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency.
    Jääskeläinen J; Voutilainen R
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):707-13. PubMed ID: 9039336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual energy X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens.
    Dubois EF; Röder E; Dekhuijzen PN; Zwinderman AE; Schweitzer DH
    Chest; 2002 May; 121(5):1456-63. PubMed ID: 12006428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.
    Rymuza J; Popow M; Żurecka Z; Przedlacki J; Bednarczuk T; Miśkiewicz P
    Endocrine; 2019 May; 64(2):308-315. PubMed ID: 30506426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of androgen excess and bone mineral density in women with classical congenital adrenal hyperplasia with 21-hydroxylase deficiency.
    Lee DH; Kong SH; Jang HN; Ahn CH; Lim SG; Lee YA; Kim SW; Kim JH
    Arch Osteoporos; 2022 Mar; 17(1):45. PubMed ID: 35258698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density in girls with classical congenital adrenal hyperplasia due to CYP21 deficiency.
    Elnecave RH; Kopacek C; Rigatto M; Keller Brenner J; Sisson de Castro JA
    J Pediatr Endocrinol Metab; 2008 Dec; 21(12):1155-62. PubMed ID: 19189689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal bone health in young adults with 21-hydroxylase enzyme deficiency undergoing glucocorticoid replacement therapy.
    Borges JH; de Oliveira DM; de Lemos-Marini SHV; Geloneze B; Guerra-Júnior G; Gonçalves EM
    Osteoporos Int; 2022 Jan; 33(1):283-291. PubMed ID: 34406442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency.
    Falhammar H; Filipsson H; Holmdahl G; Janson PO; Nordenskjöld A; Hagenfeldt K; Thorén M
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4643-9. PubMed ID: 17878254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral density and bone turnover in Romanian children and young adults with classical 21-hydroxylase deficiency are influenced by glucocorticoid replacement therapy.
    Zimmermann A; Sido PG; Schulze E; Al Khzouz C; Lazea C; Coldea C; Weber MM
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):477-84. PubMed ID: 19170706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency.
    Chakhtoura Z; Bachelot A; Samara-Boustani D; Ruiz JC; Donadille B; Dulon J; Christin-Maître S; Bouvattier C; Raux-Demay MC; Bouchard P; Carel JC; Leger J; Kuttenn F; Polak M; Touraine P;
    Eur J Endocrinol; 2008 Jun; 158(6):879-87. PubMed ID: 18390993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of Bone Mineral Parameters with Anthropometric Measurements and the Effect of Glucocorticoids on Bone Mineral Parameters in Congenital Adrenal Hyperplasia.
    Ganesh R; Suresh N; Janakiraman L; Ravikumar K
    Indian J Pediatr; 2016 Feb; 83(2):126-30. PubMed ID: 26223873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis.
    Kaji H; Yamauchi M; Chihara K; Sugimoto T
    Endocr J; 2006 Feb; 53(1):27-34. PubMed ID: 16543669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone mineral density and body composition in prepubertal and adolescent patients with the classical form of 21-hydroxylase deficiency.
    Sahakitrungruang T; Wacharasindhu S; Supornsilchai V; Srivuthana S; Kingpetch K
    J Med Assoc Thai; 2008 May; 91(5):705-10. PubMed ID: 18672636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased serum osteoprotegerin in patients with primary adrenal insufficiency receiving conventional hydrocortisone substitution.
    Fichna M; Zurawek M; Fichna P; Gryczynska M; Nowak J; Ruchala M
    J Physiol Pharmacol; 2012 Dec; 63(6):677-82. PubMed ID: 23388484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase deficiency.
    Sciannamblo M; Russo G; Cuccato D; Chiumello G; Mora S
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4453-8. PubMed ID: 16926248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mineral density and fractures in congenital adrenal hyperplasia: Findings from the dsd-LIFE study.
    Riehl G; Reisch N; Roehle R; Claahsen van der Grinten H; Falhammar H; Quinkler M
    Clin Endocrinol (Oxf); 2020 Apr; 92(4):284-294. PubMed ID: 31886890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
    Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
    Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.